Working Groups

Latest News

Register now

ISAC is proud to support the upcoming 4th International Conference on Polymyxins.

Read More
Travel Grants to attend ...

Apply for Young Investigator &Eastern Europe Travel Grants for Istanbul.

Read More


Current Officers

R Babela


Robert Babela

M Parker


Mark Parker

V Naterajan


Vivek Naterajan


Tanja Novakovic

All Members

Maryam Alowayesh (Kuwait)
Hamad Alsultan (Kuwait)
Zuzana Balazova (Slovakia)
Dragana Baltezarevic (Serbia)
Branislav Jadud (Slovakia)
Manfred Lutz (Costa Rica)
Robert Mamrilla (Slovakia)
Tanja Novakovic (Serbia)
Zuzana Srncova (Slovakia)
Ranko Stevanović (Croatia)
Tomas Tesar (Slovakia)
Danka Tešić (Serbia)
Vladimir Uraz (Slovakia)



How to Join

ISAC Working Groups are open to new members with a strong interest and relevant experience in the given field. To join an ISAC Working Group, please contact Fee Johnstone, ISAC Executive Officer with your name and a brief C.V. We welcome new members!

Aims and Objectives

Our understanding of the pharmacoeconomics of antiinfective chemotherapy has improved and has reached the point where this science should be taken into consideration not only for the proper development of new agents but also for the proper clinical use of antimicrobial agents. Pharmacoeconomic evaluation of new drugs and/or health technology assessment became a necessary part of many reimbursement procedures around the world, especially in Europe. We need to provide more insights into current practices and use researchers, regulators and clinicians to help us understand the value of new technology in a time of health budget constraints and strict drug policies. While this is now more and more recognized by academia, industry and regulatory agencies, there is presently a need for further training in this field.

The aims of the Working Group are to promote the international exchange of ideas and new research into all aspects of pharmacoeconomics (PE), also in collaboration with other scientific societies (i.e. ISPOR).

Our Work Plan is as follows:

  • Organise a workshop on PE during the biannual ICC congress
  • Organise occasional educational meetings
  • Encourage scientific exchange with other scientific organisations
  • Implement the PE approach in anticancer/antiinfective therapy
  • Apply for research grants

The most recent meeting of the Working Group took place 27th March 2015 in Chigago during the MBAA International Conference.

Presentations / Meeting Participation

13 November 2019

Information Technology and Public Administration (ITAPA) Congress, Bratislava, Slovaki
Robert Babela: Data economics in healthcare: examples from selected therapeutics areas

16-21 September 2019

Canadian Agency for Drugs and Technologies in Health (CADTH), Ottawa, Chicago

27-29 March 2019

Midwest Business Administration Association (MBAA), Chicago, USA

May 2019

International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 2019, New Orleans, USA

March 2019

Decision making in practice, Serbia

October 2018

VII Serbian Congress of Pharmacy, Belgrade, Serbia

13 November 2015

6th South European Conference on Chemotherapy and Infection

Pharmacoeconomics in antimicrobial treatment: trends, challenges and opportunities

Chair: Robert Babela (Slovakia)
Co-chair: Mark Parker (UK)

  • Economic evaluations in time of increasing antimicrobial resistance in community: Robert Babela (Slovakia)
  • Antimicrobial Agents and Current Pricing and Reimbursement Policies Across Europe: Tanja Novakovic (Serbia)
  • Economical evaluation of drugs in Slovakia as the main conditional for reimbursement and its impact on innovation in treatment of infectious diseases: Elena Marusakova (Slovakia)
  • Modeling issues in Antimicrobial Treatment: Mark Parker (UK)

(Sponsored by: International Society of Antimicrobial Chemotherapy's PHARMACOECONOMICS Working Group)

25-27 March 2015

The 51st Annual MBAA International Conference

  • Mandatory Generic Substitution in Slovakia: Quo Vadis? Robert Babela, St. Elizabeth University 
  • The Role of the Ministry of Health in the Accreditation Process of Healthcare Programs in Slovakia: 5-Year Review: Robert Babela, St. Elizabeth University 
  • The Debt Evolution in Healthcare System in the Slovakia Republic from 2003 to 2013: Robert Babela, St. Elizabeth University

Projects / Publications

2017 Pharmacoeconomics Annual Report 2017
2014-2015 Empirical therapy for respiratory tract infections in an era of increasing antimicrobial resistance: a decision and cost analysis.
Project supported by MSD Slovakia, paper with results submitted for publication
2014-2015 Knowledge, belief and attitude of General Practitioners, Pediatricians and selected specialists in prescribing cephalosporines, macrolides and broad- spectrum penicillins for Respiratory Tract Infections (RTIs) in Slovakia - a prospective study.
Project supported by MSD Slovakia, results under statistical evaluation, first data will be submitted to ISPOR 2015 in Milan, Italy.

Future / Ongoing Activities

**Some of the proposed 2020 meetings were postponed / cancelled due to COVID-19**

  • Midwest Business Administration Association (MBAA), Chicago, March 2020, Chicago, USA (WG Pharmacoeconomics committee meeting, preliminary
  • Seventh International Conference of the Pharmacoeconomics Section of the Pharmaceutical Association of Serbia (SFE SFUS), March, 2020
  • International Society for Pharmacoeconomics and Outcomes Research (ISPOR), May 2020, Orlando, USA
  • Serbian Congress of Pharmacy, October 2020, Belgrade, Serbia
  • International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Milan 2020, November 2020, Milan, Italy
  • The Association of University Programs in Health Administration (AUPHA), Philadelphia, USA

Cost-of-illness projects focused on population disease burden from the payers’ perspective: cost of depression, cost of asthma, cost of allergy.

Last updated: October 26th-2020